With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.
(28A) tert-Butyl{3-[4-(3,4-dichlorobenzyloxy)phenyl]-3-vinyloxypropoxy}dimethylsilane3-(tert-Butyldimethylsilyloxy)-1-[4-(3,4-dichlorobenzyloxy)phenyl]propan-1-ol (300 mg, 0.680 mmol) produced in Example 27 (27B), palladium(II) trifluoroacetate (12 mg, 0.036 mmol), and 4,7-diphenyl-1,10-phenanthroline (12 mg, 0.036 mmol) were dissolved in butyl vinyl ether (5 mL), and triethylamine (20 muL, 0.14 mmol) was added thereto, and the resulting mixture was stirred under a nitrogen atmosphere at 80 C. for 4 hours. After cooling to room temperature, the reaction solution was filtered, and the solvent was distilled off under reduced pressure, whereby a crude product was obtained. This crude product was purified by silica gel column chromatography (hexane:ethyl acetate=100:0 to 96:4 (v/v)), whereby the objective title compound was obtained as a colorless oily substance (275 mg, yield: 87%).1H NMR (CDCl3, 400 MHz): delta0.04 (3H, s), 0.05 (3H, s), 0.91 (9H, s), 1.85 (1H, m), 2.07 (1H, m), 3.41 (1H, m), 3.57 (1H, m), 3.95 (1H, dd, J=1.6, 6.6 Hz), 4.23 (1H, dd, J=1.6, 14.1 Hz), 4.90 (1H, dd, J=5.1, 8.2 Hz), 5.00 (2H, s), 6.29 (1H, dd, J=6.6, 14.1 Hz), 6.92 (2H, d, J=9.0 Hz), 7.22 (2H, d, J=9.0 Hz), 7.24-7.28 (2H, m), 7.45 (1H, d, J=8.6 Hz), 7.54 (1H, d, J=2.0 Hz)
1662-01-7, 1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; DAIICHI SANKYO COMPANY, LIMITED; US2011/53974; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI